News

DSM enters algae alliance
Enlarge image

BusinessFranceGermany

DSM enters algae alliance

12.10.2012 - Dutch Royal DSM collaborates with a Sanofi subsidiary to stretch ist algal expression system into animal health vaccine production.

This strategic alliance could change the established ways of vaccine production. DSM Nutritional Product, a subsidiary of Dutch Royal DSM N.V., has announced a Development and Option to License Agreement with animal health specialist Merial Limited, part of the US-subsidiary of French Sanofi S.A. The partners want to bring together their expertise to produce animal health vaccines in DSM’s proprietary algal expression system. Compared to existing techniques based on eggs or cell cultures, the new platform could present a faster and more efficient production method. Financial details were not disclosed. It is known, however, that Merial will provide R&D funding to value DSM’s research efforts. DSM would also be eligible to receive milestone payments, license fees and royalties on sales of a successfully launched product.

Almost two years ago Royal DSM acquired Martek Biosciences Corporation from Columbia (Maryland, USA) in a billion dollar deal. This marked DSM’s transformation into a life sciences and materials sciences company. In Columbia omega-3- and omega-6-products are produced by algae. Former Martek CEO Peter Nitze, now President of the Nutritional Lipids division of DSM Nutritional Products, welcomes the expansion of the algae-production portfolio: „We are pleased to join Merial on this important project that we expect will validate the algal expression system as a viable alternative to known vaccine production methods.“ DSM is better known as a global player in biofuel production. The company hit the news earlier this year when it announced the start of a joint venture with US-ethanol producer POET, LLC.

© eurobiotechnews.eu/ml

http://www.european-biotechnology-news.com/news/news/2012-04/dsm-wants-algae-made-vaccines.html

FinancingBelgium

28.04.2015 After having raised €100m in its stock market debut, MDx company Biocartis has gained 13 percent on its first trading day.

R&DFranceUKSweden

24.04.2015 AstraZeneca has boosted its oncology portfolio by signing a US$1.275bn agreement with Innate Pharma. The companies plan to further the development of Innate’s tumour-targeting antibody.

PoliticsEU

22.04.2015 A legislative proposal by the European Commission is set to renationalise market authorisation of genetically modified crops.

FinancingUK

21.04.2015 Ahead of its listing on the London Stock Exchange, Woodford’s Patient Capital Trust has raised a record sum of €1.1bn. The fund met with immense interest by investors.

Swiss Biotech DaySwitzerland

16.04.2015 The Swiss biotech industry can look back on 2014 as a good year, but political uncertainties do remain. This was one of the topics discussed during the Swiss Biotech Day in Basel, which attracted more than 400 participants.

EventEUFrance

16.04.2015 The changing landscape in healthcare was just one of the hotly discussed topics of the 27th Annual EuroMeeting of the international association DIA.

R&DBelgium

14.04.2015 Belgian Thrombogenics NV has launched a new oncology company with Gent-based life sciences institute VIB. The new venture will develop an antibody for the treatment of a fast-growing brain tumour that affects children and adolescents.

Stock MarketsEUFranceUKNorwaySweden

09.04.2015 The European public markets remain highly attractive for biotech companies. Twice as many companies went public in the first quarter of 2015 than during the same period last year.

FinancingAustriaUKSwitzerlandGermany

08.04.2015 To bring its lead product of a new class of antimicrobials to phase 3 trials, Nabriva Therapeutics has completed a US$120m Series B financing.

Research & DevelopmentNetherlands

07.04.2015 Gene therapy is attracting more and more big pharma companies. Now, Bristol-Myers Squibb has forged a US$1bn collaboration with Dutch uniQure, also picking up a 4.9% share in the company.

Events

All Events

Partner-Events

München

BioVaria 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • WILEX4.84 EUR34.82%
  • FORMYCON31.25 EUR11.61%
  • PAION2.76 EUR6.98%

FLOP

  • MEDIGENE12.41 EUR-3.42%
  • SANTHERA96.75 CHF-2.12%
  • MOLOGEN5.01 EUR-1.18%

TOP

  • WILEX4.84 EUR63.5%
  • FORMYCON31.25 EUR35.0%
  • CO.DON3.35 EUR29.8%

FLOP

  • CYTOS1.08 CHF-22.9%
  • BIOTEST78.40 EUR-18.9%
  • THERAMETRICS0.07 CHF-12.5%

TOP

  • SANTHERA96.75 CHF2368.1%
  • CYTOS1.08 CHF671.4%
  • WILEX4.84 EUR469.4%

FLOP

  • MOLOGEN5.01 EUR-55.5%
  • BIOFRONTERA2.40 EUR-26.8%
  • THERAMETRICS0.07 CHF-22.2%

No liability assumed, Date: 27.04.2015